TWI916635B - 西維美林水溶液組合物和使用方法 - Google Patents

西維美林水溶液組合物和使用方法

Info

Publication number
TWI916635B
TWI916635B TW112101732A TW112101732A TWI916635B TW I916635 B TWI916635 B TW I916635B TW 112101732 A TW112101732 A TW 112101732A TW 112101732 A TW112101732 A TW 112101732A TW I916635 B TWI916635 B TW I916635B
Authority
TW
Taiwan
Prior art keywords
aqueous solution
composition
solution composition
syndrome
concentration
Prior art date
Application number
TW112101732A
Other languages
English (en)
Chinese (zh)
Other versions
TW202329958A (zh
Inventor
張金明
羅倫 波德米爾
Original Assignee
張金明
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 張金明 filed Critical 張金明
Publication of TW202329958A publication Critical patent/TW202329958A/zh
Application granted granted Critical
Publication of TWI916635B publication Critical patent/TWI916635B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112101732A 2022-01-25 2023-01-16 西維美林水溶液組合物和使用方法 TWI916635B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/US22/13586 2022-01-25
US2022013586 2022-01-25

Publications (2)

Publication Number Publication Date
TW202329958A TW202329958A (zh) 2023-08-01
TWI916635B true TWI916635B (zh) 2026-03-01

Family

ID=87472506

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112101732A TWI916635B (zh) 2022-01-25 2023-01-16 西維美林水溶液組合物和使用方法

Country Status (4)

Country Link
EP (1) EP4469047A4 (enExample)
JP (1) JP2025502242A (enExample)
TW (1) TWI916635B (enExample)
WO (1) WO2023147318A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO2024016594A1 (es) * 2024-12-02 2024-12-09 Espec Oftalmologicas S A Colirio oftalmológico y/o vehículo farmacéutico indicado para el restablecimiento y la protección de la histéresis de la película lagrimal

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180280363A1 (en) 2013-08-28 2018-10-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
CN110099681A (zh) 2016-10-04 2019-08-06 塞尔利克斯生物私人有限公司 用于治疗口腔干燥症的组合物和方法
US20210369686A1 (en) 2018-10-06 2021-12-02 Biotheravision Llc Ophthalmic preparations of muscarinic agonist and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
EP3749303A4 (en) * 2018-02-05 2022-01-26 Cellixbio Private Limited COMBINATION OF AN ANTIMUSCARINE OR ANTICCHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
BR112021006618B1 (pt) * 2018-10-10 2022-09-27 Presbyopia Therapies, Inc Composições e métodos para o tratamento da presbiopia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180280363A1 (en) 2013-08-28 2018-10-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
CN110099681A (zh) 2016-10-04 2019-08-06 塞尔利克斯生物私人有限公司 用于治疗口腔干燥症的组合物和方法
US20210369686A1 (en) 2018-10-06 2021-12-02 Biotheravision Llc Ophthalmic preparations of muscarinic agonist and methods of use

Also Published As

Publication number Publication date
WO2023147318A2 (en) 2023-08-03
EP4469047A4 (en) 2026-03-04
WO2023147318A3 (en) 2023-09-21
TW202329958A (zh) 2023-08-01
JP2025502242A (ja) 2025-01-24
EP4469047A2 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
EP1575597B1 (en) Use of rimexolone in the treatment of dry eye
US20120093876A1 (en) Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
JP7465453B2 (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
AU2008219600A1 (en) Methods and compositions for normalizing meibomian gland secretions
CN101754748A (zh) 治疗干眼症的制剂和方法
AU2007208054A1 (en) Formulations and methods for treating dry eye
CN116236471A (zh) 用于预防和/或治疗干眼症的组合物、方法和/或装置
JP2021501803A (ja) 近視の進行を制御し且つ／又は減少させるための医薬組成物
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
WO2020072971A1 (en) Ophthalmic preparations of muscarinic agonist and methods of use
WO2020011845A1 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
TW202329958A (zh) 西維美林水溶液組合物和使用方法
TW202337462A (zh) 採用長春西汀治療近視的方法
TWI809317B (zh) 蕈毒鹼性促效劑眼用製劑及其用途
EP4093372B1 (en) Ophthalmic composition for the treatment of dry eye disease
HK1076248B (en) Use of rimexolone in the treatment of dry eye
AU2019230220A1 (en) Methods of use and pharmaceutical compositions of a selective Syk inhibitor
HK1201464A1 (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
HK1178446B (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives